Two main types of therapy-related acute myeloid leukemias (tAML) and myelodysplastic syndromes (tMDS) have been described. The first classical type typically occurs late after use of alkylating agents and presents as MDS with −7/del 7q and/or −5/del5q. The second form occurs early after the use of agents targeted at topoisomerase II, and presents as AML with 11q23 or other rearrangements of de novo AML. Recently, we and others reported, in AML and MDS, a strong correlation between cytogenetic rearrangements leading to 17p deletion, a specific type of dysgranulopoiesis and p53 mutation; several of those cases of 17p− syndrome were therapy-related. Over the last 15 years, we observed 25 cases of tAML and tMDS with 17p deletion, which represented 36% of the AML and MDS with 17p deletion diagnosed during that period. Median age was 59 years. Twenty-one patients had tMDS and four tAML. Typical dysgranulopoiesis and p53 mutation and/or overexpression were seen in 22 of 24 and 16 of 19 evaluable patients, respectively. 17p deletion resulted from unbalanced translocations involving 17p (18 cases), monosomy 17 (five cases), i(17q) (one case) or del 17p (one case). Twenty-one patients also had −5/del 5q, and/or −7/del 7q. Median interval from treatment of the first tumor of tAML and tMDS was 94 months (range 19-252). Median survival was only 7 months. Based on primary tumor and antineoplastic agents used, patients could be relatively well divided into two groups: a first group of 11 cases, occurring mainly after a lymphoid neoplasm (eight cases) treated by chemotherapy with an alkylating agent (10 cases), and a second group of 14 cases occurring after essential thrombocythemia (ET) or polycythemia vera (PV) treated mainly by hydroxyurea (10 cases), pipobroman (eight cases), 32 P (six cases) but rarely by alkylating agents (two cases). −7/del 7q was found in 10 of the 11 patients in the first group, as compared to three of the 14 patients of the second group (P ‫؍‬ 0.0001). Therefore, therapy-related cases represent a high proportion of AML and MDS with the 17p− syndrome. They have many features in common with classical tMDS and tAML, including long interval from the first tumor, a usual preleukemic phase, and frequent occurrence of −5/del 5q. About one half of them, in addition, occur after alkylating agents and generally carry −7/del 7q. The other half, however, occur mainly after ET or PV treated by hydroxyurea or other non-alkylating agents, and usually have no −7/del 7q. These findings bring further support to a possible relationship between prior drugs used and cytogenetic rearrangements in tAML and tMDS.
Introduction
Myelodysplastic syndromes (MDS) are stem cell disorders characterized by ineffective hematopoiesis leading to blood cytopenias, and by a high risk of progression to acute myeloid leukemia (AML). 1 MDS and AML can arise apparently de novo or be secondary to the administration of antineoplastic agents (therapyCorrespondence: P Fenaux, Service des Maladies du Sang, CHU, 1 Place de Verdun 59037, France Received 11 June 1998; accepted 26 October 1998 related MDS or AML). Two main types of therapy-related MDS and AML have been reported. 2 The first classical type generally occurs 3 to 7 years after prolonged administration of alkylating agents, and presents as MDS with cytogenetic abnormalities generally involving chromosome 7 and/or 5, and often complex karyotype. 3, 4 The second type, more recently described, usually occurs with a shorter interval, after administration of agents targeted at topoisomerase II (ATTo II, including the epipodophyllotoxin agents VP16 or VM26, and anthracyclines and their derivatives), presents as AML, not preceded by a phase of MDS, and has cytogenetic rearrangements usually observed in de novo AML, including rearrangements of 11q23, but also, as found in particular by our group, t(8;21), inv (16) , t(15;17) and more rarely t(8;16). [5] [6] [7] [8] [9] Recently, we and others reported, in AML and MDS, a strong correlation between cytogenetic rearrangements leading to 17p deletion (unbalanced translocation between chromosome 17 and another chromosome, monosomy 17 or less often i(17p)), a specific type of dysgranulopoiesis combining pseudo Pelger-Hü et hypolobulation and vacuoles in neutrophils, and p53 mutation. [10] [11] [12] These correlations suggested that MDS and AML with 17p deletion could constitute a new morphological-cytogenetic-molecular entity, the 17p− syndrome. In our initital report of 47 cases with the 17p− syndrome, 10 were therapy-related.
We have now diagnosed 69 cases of MDS and AML with the 17p− syndrome, and 25 of them (36%) were therapyrelated. We report here their characteristics, especially with regard to prior neoplasm and antineoplastic agents administered.
Patients and methods

Patients
Between 1982 and 1996, we performed cytogenetic analysis in 755 cases of MDS and 754 cases of AML, classified according to FAB criteria. 13 Sixty-nine of them (4.6%) had cytogenetic rearrangements leading to 17p deletion. Twenty-five of the 69 cases (36%), which occurred after a prior neoplasm treated with chemotherapy and/or radiotherapy, constitute the basis of this work.
Methods
Cytogenetic analysis:
Cytogenetic analysis was made on unstimulated bone marrow 24 h culture after G and R banding, and chromosome abnormalities were classified according to the Human System for Cytogenetic Nomenclature (ICSN). 14 In 19 of the 25 patients, cytogenetic findings and in some cases hematological findings had been previously reported (Table 1) . 10, 12, 15 Six of those 19 patients had also been studied (48) der (17) Analysis of p53 mutations and of p53 expression Detection of p53 mutations was made by single stranded conformation polymorphism analysis of exons 4 to 10, and analysis of p53 expression by immunocytochemistry on bone marrow slides, as previously published. 16, 17 In our experience in AML and MDS, detection of p53 protein by this immunocytochemical method is synonymous with the presence of a p53 gene missense mutation.
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Results
Clinical and hematological characteristics of the 25 patients with therapy-related MDS or AML and 17p deletion
These are shown in Table 1 , median age was 59 years (range 14-83) and there were 12 males and 13 females. At diagnosis of the second neoplasm, 21 patients had MDS, including refractory anemia (RA) in three cases, refractory anemia with excess of blasts (RAEB) in 14 cases, and RAEB in transformation (RAEB-T) in four cases; the remaining four patients had AML, including M2 AML in three cases and M4 AML in one case.
Typical features of dysgranulopoiesis previously observed in MDS and AML with 17p deletion, 10,11 including pseudo Pelger-Hü et hypolobulation and small vacuoles in at least 5% of neutrophils, were found in 22 cases, absent in two patients (Nos 17 and 21) and not evaluable in the remaining case (No. 20), due to the poor quality of bone marrow slides. Myelodysplastic features were also generally present in other lineages, but no dysmegackaryopoiesis typical of the 5q− syndrome 18 was seen in any patient. Cytogenetically, 18 patients had unbalanced translocation between chromosome 17 and another chromosome, including chromosome 5 in eight cases, chromosome 7 in three cases, chromosome 1 in one case, whereas in six cases the chromosome segment translocated on 17p was undetermined (add 17p); one patient had del 17p, five patients had monosomy 17 and one patient had i(17q). All those chromosome 17 rearrangements cytogenetically resulted in 17p deletion (Table 1) . Twenty-four of the 25 patients had one or several additional cytogenetic rearrangements, involving chromosome 5 and/or 7 in 21 of them: monosomy 5 in 14 cases, monosomy 7 in 12 cases, del 5q in six cases, and del 7q in one case. In six patients (Nos 3, 4, 6, 9, 14, 19) WCP and FISH analysis were also performed. They confirmed cytogenetic results, except in patient No. 4, where they modified the interpretation from der (17)t(5;17) to der(5)t(5;17). In patient No. 14, WCP with probes for chromosomes 5, 7, 12, 18, 21, 22 was unable to identify the partner chromosome of 17 in the translocation.
A p53 mutation and/or p53 expression was found in 16 of the 19 evaluable cases (Table 1) . Mutations included p53 gene rearrangement detectable by Southern analysis in one patient, and point mutation involving exons 5, 7 or 8 in nine patients. Direct sequencing of the mutated exon, performed in seven of them, showed that the mutation occurred in known mutation hotspots of p53 mutations observed in leukemias and other neoplasms. 19 After diagnosis of MDS or AML, two patients were allografted, four received intensive anthracycline-Ara-C chemotherapy, two low-dose Ara-C and the remaining patients received supportive care only. Median survival was only 7 months (range 1-72+, Table 1 ).
Primary tumor and antineoplastic agents received
The primary tumor was polycythemia vera (PV) in seven cases, essential thrombocythemia (ET) in seven cases, multiple myeloma (MM) in four cases, Hodgkin's disease (HD) in three cases, acute lymphoid leukemia (ALL) in one case, AML in one case and solid tumor in two cases. In the patient with AML as first tumor, the first AML was morphologically M1 AML, without preleukemic phase and with normal karyotype. This patient had been in complete remission for 15 years after chemotherapy, when cytopenias appeared and RAEB with the 17p − syndrome was diagnosed. Progression to M2 AML was seen after 15 months. Therefore this MDS was considered as a secondary leukemia rather than as relapse of the first AML. Likewise, in the patient with ALL as first tumor, review of the file showed initially typical Calla-positive ALL, with normal karyotype. The patient had remained in CR during 10 years after which RAEB-T was diagnosed, strongly supporting a secondary leukemia rather than relapse of the first one. Five and one of the patients with ET and PV as primary tumor, respectively, had been karyotyped at diagnosis of ET and PV, and normal findings had been observed in all cases.
As seen in Table 2 , 12 patients had received one or several Interval from the onset of treatment for the primary tumor and diagnosis of therapy related MDS or AML ranged from 19 to 252 months (median 94). Eleven of the 12 patients who had received alkylating agents had, in addition to 17p deletion, monosomy 7 or del 7q, as compared to two of the 13 patients who had not received those drugs for the treatment of their primary tumor (P = 0.0001 by Fisher's exact test). In addition, only three of the 14 patients with essential thrombocythemia or polycythemia vera as primary tumor had monosomy 7 or del 7q, as compared to 10 of the 11 patients with other types of initial tumors (P = 0.002 by Fisher's exact test). On the other hand, no differences in the incidence of monosomy 5 and del 5q were seen according to previous administration or not of alkylating agents, and according to primary tumor.
Based on the type of primary tumor and treatment received for this tumor, it appeared that the 25 cases of AML and MDS with 17p deletion could be relatively well divided into two groups: a first group of 11 patients with different types of neoplasms (but mainly a lymphoid malignancy), who had received combination chemotherapy (10 cases) or radiotherapy alone (one case). Chemotherapy had included at least one alkylating agent in all cases. Monosomy 7 or del7q was present in 10 of the 11 cases, including all the 10 patients who had received chemotherapy. Median interval from the onset of treatment for the primary tumor and MDS or AML was 84 months. The remaining 14 patients apparently constituted a second group with chronic myeloproliferative disorder (MPD), ET or PV, as primary tumor; those patients had been treated by hydroxyurea (10 cases), pipobroman (eight cases), radiophosphorous (six cases) but had received classical alkylating agents (busulfan) in only two cases. Only three of the 14 patients had monosomy 7, including one of the patients treated with busulfan. Median interval from the onset of treatment for the primary tumor was 95 months.
Discussion
Cytogenetic rearrangements leading to 17p deletion, through unbalanced translocation between chromosome 17p and another chromosome, monosomy 17 or i (17) , are observed 10 to 15% of cases of therapy-related MDS or AML, almost always in association with other cytogenetic rearrangements. 4, 5 On the other hand, approximately 630 cases of MDS and AML with rearrangements leading to 17p deletion have been computed from the literature by Mitelman, and about 150 (23%) of them were therapy-related. 20 The 25 patients reported here generally also had other characteristics of the 17p − syndrome described by our group and other authors: typical dysgranulopoiesis combining pseudo Pelger-Hü et hypolobulation and small vacuoles in at least 5% granulocytes (92% of the cases), p53 mutation (84% of the evaluable cases) and additional complex cytogenetic findings (96% of the cases). 10, 11 Those features were found with similar frequency, in our experience, in de novo MDS and AML with 17p deletion. 10 In addition, de novo and therapy-related cases had a similar incidence of additional monosomy 7 or del7q (46% in our de novo cases, as compared to 52% in the present therapy-related cases) and similar age at diagnosis (median 68 years in our de novo cases, as compared to 59 years in the present therapy-related cases). 10 Our 25 patients had many of the features of classical therapy-related leukemia:
3,4,6 relatively long interval from onset of treatment of the first tumor in most of the cases, detectable preleukemic phase in 21 of them (who presented with MDS), complex cytogenetic findings in 24 patients, with involvement of chromosomes 5 and/or 7 in 21 of them. Among the 25 cases, 11 cases that occurred mainly after a lymphoid malignancy, had received alkylating agent containing chemotherapy (10 cases) and also had monosomy 7 or del 7q (10 cases) constituted a first group, which had indeed all the major characteristics of classical therapy-related leukemia. 4, 5 A second group of 14 patients somewhat differed from the typical picture in that the primary tumor was chronic MPD (ET or PV), treated predominantly with hydroxyurea (10 cases), pipobroman (eight cases) and 32 P (six cases) but rarely (two patients) with classical alkylating agents. Furthermore monosomy 7, in this group, was seen in only three cases, including one of the two patients who received busulfan.
The incidence of progression to AML and MDS is about 1% in PV patients treated with phlebotomy alone, 21, 22 and very low in ET patients who do not receive antineoplastic agents. 23 On the other hand, antineoplastic agents generally used in ET and PV all appear to be associated with an increased risk of progression to leukemia: the incidence of progression to AML and MDS in PV treated by 32 P and classical alkylating agents, is in the range of 6 to 10% and 12 to 13%, respectively; 21, 22 in PV and ET treated with hydroxyurea alone for prolonged periods, it is in the range of 3 to 4% and 5 to 6%, respectively. [23] [24] [25] [26] [27] In PV and ET treated with pipobroman (a bromide derivative of piperazine which, although its formula is close to that of the alkylating agents, mainly appears to act as a metabolic competitor of pyrimidine cases) the leukemic risk appears to be of about 5 to 6%, respectively. 23, [27] [28] [29] By reviewing published literature, we found 36 cases and 132 cases of AML or MDS occurring after ET and PV, respectively, with karyotype available at transformation. 25, Nineteen of them had rearrangements leading to 17p deletion, and 32 had monosomy 7 or del 7q. 17p deletion was more frequent than monosomy 7/del7q in patients treated with hydroxyurea (eight vs five cases) and 32 P (10 vs seven cases) whereas the reverse situation was seen in patients treated with alkylating agents (10 vs25 cases). More precisely, 17p deletion was found in only one of the 50 (2%) patients treated with alkylating agents alone, as compared to three of the 31 (10%) patients treated with 32 P alone, and six of the 17 (35%) patients treated with hydroxyurea alone. These data support our findings, in MDS and AML occurring during the course of ET and PV, of an association between hydroxyurea and to a lesser extent 32 P and 17p deletion. On the other hand, alkylating agents appear to preferentially result in MDS and AML with −7/del7q, only occasionally associated to 17p deletion. Our findings possibly also support an increased risk of AML and MDS with 17p deletion in PV and ET treated with pipobroman. However, because this drug has not been widely used, very few published data are available to confirm these results.
Progression to AML in chronic myeloid leukemia (CML), another chronic MPD, is often associated with 17p deletion and other features of the 17p− syndrome. 62, 63 Therefore hydroxyurea, 32 P and pipobroman, in ET and PV, could only increase or trigger a genetic susceptibility of those disorders to progress to leukemia with 17p deletion. This is however not supported by the fact that untreated ET and PV treated by venesection only very rarely progress to AML, 21, 23 and that AML and MDS occurring in ET and PV treated with alkylating agents alone rarely have 17p deletion.
In conclusion, our results suggest that therapy-related AML and MDS with 17p deletion have many features in common with classical therapy-related leukemias, including relatively prolonged interval from treatment of the first tumor, a preleukemic phase and complex cytogenetic findings. About half of them, in addition, are particularly typical in that they occur mainly after lymphoid malignancies treated with alkylating agents and have monosomy 7 or del 7q. The remaining half, however, unexpectedly occur in ET or PV treated mainly by hydroxyurea, 32 P or pipobroman, and rarely carry a chromosome 7 abnormality. These findings bring further support to a possible relationship between prior antineoplastic agents used and cytogenetic rearrangements observed in therapy-related AML and MDS. This relationship will have to be further explored, especially at the molecular level.
